Anique Ducharme, MD (she/her/hers)

Cardiologist
CCS, CCTN, CHFS, CANCARE
University of Montreal

Dr. Ducharme is a Professor of Medicine and holder of the University of Montreal Coutu-Moisan chair for best practices in advanced Heart Failure. She is the founder and Director of the Heart Failure Clinic at the Montreal Heart Institute, president of the Canadian Heart Failure Society and was the Scientific Program Committee Chair for the Canadian Cardiovascular Congress (CCC, from 2018-2020), where she implemented a mandatory 3G politics for all workshops being presented, to promote diversity in terms of gender, geography and generation; she also led the pivot from a in-person to a fully virtual meetin for CCC2020. She has been (and still is) on the CCS Heart Failure Guidelines Committee since 2006 and is the program director for the University of Montreal Advanced Heart Failure and Cardiac transplantation fellowship program. She has published over 165 peer-reviewed articles including in the NEJM, Lancet and Circulation, 16 book chapters, 200 abstracts and 2 online university tutorial courses and is currently serving or has served on several leadership committees for large-scale studies, including GUIDE-HF, VICTOR, STICH, AF-CHF, EARTH, RELAX-HF and CHARM. She is an associate editor for the International Journal of Cardiology: Heart and Vasculature and also participates in several review panels for many journals,
Dr. Ducharme graduated from Université de Montréal in Medicine (MD) and Biomedical sciences (MSc, cardiac transplantation) (1991) and Cardiology(1996), followed by a fellowship at the Brigham & Women’s Hospital, Harvard Medical School (Boston). Since her return in 1999, she has held a position in the Non-invasive Cardiology department at the Montreal Heart Institute, where she carries out activities in echocardiography, advanced heart failure and cardiac transplantation. Her clinical and research focus is on advanced heart failure, including remodeling, pharmacological and device therapies (cardiac resynchronization therapy, percutaneous valvular interventions, pulmonary pressure monitoring, mechanical assist devices) and cardiac transplantation.

Disclosure information not submitted.

Presentation(s):

• PAVING THE TRANSITION FROM TRAINING TO EARLY CAREER: WITH A VEIW TO SUCCESS (CCC-127)

  Thursday, October 26, 2023
  15:15 – 16:15 EST

• CARDIOGENIC SHOCK PROGRAM: BEYOND THE 'COLD AND WET' PHENOTYPE IN CARDIOGENIC SHOCK - PART A (CCC-216)

  Friday, October 27, 2023
  08:30 – 09:15 EST

• CARDIOGENIC SHOCK PROGRAM: BEYOND THE 'COLD AND WET' PHENOTYPE IN CARDIOGENIC SHOCK - PART B (CCC-220)

  Friday, October 27, 2023
  09:45 – 10:30 EST

• CARDIOGENIC SHOCK PROGRAM: NON-SURGICAL PERCUTANEOUS INTERVENTIONS IN CARDIOGENIC SHOCK (CCC-224)

  Friday, October 27, 2023
  11:00 – 11:45 EST

• IMPLICATIONS, NEED FOR ADVOCACY AND WHERE WE GO FROM HERE (CCC-231)

  Friday, October 27, 2023
  16:55 – 17:05 EST

• MODERATED Q&A (CCC-231)

  Friday, October 27, 2023
  17:05 – 17:30 EST

• INFLAMMATION AT THE INTERFACE OF ATHEROSCLEROSIS, CKD, AND HF (AS-105)

  Saturday, October 28, 2023
  07:15 – 08:15 EST